The leading pharmaceutical circulation enterprises will benefit from the further expansion of centralized mining

[trends of pharmaceutical network industry] in the early stage of China's pharmaceutical circulation industry, it showed the characteristics of "more, less, scattered and disorderly" With the promotion of medical reform policies such as two vote system and zero markup, the concentration of the industry continued to increase Recently, the circular on several policies and measures to further deepen the reform of the medical and health system with centralized purchase and use of drugs as the breakthrough point made it clear that we should promote the cross regional and cross ownership merger and reorganization of drug production and distribution enterprises, cultivate a number of large-scale enterprises and groups with international competitiveness, and accelerate the formation of pharmaceutical students with large-scale backbone enterprises as the main body and small and medium-sized enterprises as the supplement Production and circulation pattern The volume purchase policy is also a major policy that has affected the pharmaceutical market pattern since this year The industry believes that although in the short term, the impact of volume purchase policy on pharmaceutical circulation enterprises is limited, but with the further expansion of centralized procurement, the amount of pharmaceutical circulation will be further reduced In the long term, as the market concentration of pharmaceutical circulation industry will continue to improve, the leading enterprises that centralized procurement is conducive to fine management will benefit the relevant enterprises According to the public information of Sinopharm, the retail direct sales business of Sinopharm has covered the top 500 chain stores and many single drugstores in China, with direct channels covering more than 30000 stores and channel extension covering more than 80000 stores in total Anesthetic business is one of the core competitive businesses of the company Among the three national wholesale enterprises of narcotic drugs and class I psychotropic drugs, Sinopharm has always maintained 80% market share and has always been in the leading position in the industry In the first half of this year, Sinopharm's anesthetics business also entered the "big anesthetics" mode, introducing a number of category I and category II psychotropic drugs, and expanding the field of anesthetics In the first half of 2019, Sinopharm's business is still dominated by pharmaceutical circulation, with pharmaceutical distribution accounting for more than 90% of the total Sinopharm said that with the continuous deepening of the medical reform policy, due to the comprehensive nature of its business, it will inevitably be affected by various policies, such as "4 + 7" volume collection, clinical drug use monitoring, zero difference rate of devices, DRGs pilot, etc Therefore, in the future, it will continue to strengthen the strategic development layout, optimize the format structure, continue to cultivate and develop new formats and businesses, and accelerate the process of regional integration According to the data of LiuYao, LiuYao is a regional pharmaceutical circulation enterprise After more than 60 years of intensive work in the field of Guangxi pharmaceutical circulation, LiuYao has gradually formed a comprehensive pharmaceutical business system with "hospital sales business as the core, the third terminal and drugstore retail business as the wings, and business allocation as the supplement" It is reported that since this year, in the face of changes in industrial policies and intensified market competition, LiuYao has actively adjusted its business strategies, fully utilized its advantages in modern logistics technology and wholesale and retail integration channels, continuously deepened cooperation with upstream suppliers, and maintained a high variety satisfaction rate According to kyushitong, kyushitong is a company whose core business is wholesale, retail chain, drug production and research and development, as well as value-added services of drugs, medical devices and other products Jiuzhoutong is a leading enterprise in the field of medicine circulation in China The company's marketing network has covered most of China's administrative regions, maintained good cooperation with more than 10000 upstream suppliers, and is an important distributor of many well-known domestic production enterprises At the same time, nearly 20 million downstream customers, including pharmacies, hospitals, grassroots medical institutions, distributors, etc., have established close strategic cooperation with top 100 chain stores